↓ Skip to main content

Response to PD1 inhibition in conventional chondrosarcoma

Overview of attention for article published in Journal for Immunotherapy of Cancer, September 2018
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (69th percentile)

Mentioned by

twitter
9 tweeters

Citations

dimensions_citation
22 Dimensions

Readers on

mendeley
7 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Response to PD1 inhibition in conventional chondrosarcoma
Published in
Journal for Immunotherapy of Cancer, September 2018
DOI 10.1186/s40425-018-0413-z
Pubmed ID
Authors

Michael J. Wagner, Robert W. Ricciotti, Jose Mantilla, Elizabeth T. Loggers, Seth M. Pollack, Lee D. Cranmer

Abstract

Chondrosarcoma is one of the most common malignant bone tumors in adults. Conventional chondrosarcoma represents around 85% of all chondrosarcomas and is notoriously difficult to treat with chemotherapy. We describe a 67-year-old man with metastatic conventional chondrosarcoma who was treated with nivolumab. Treatment was discontinued after restaging showed increased tumor burden, which later proved to be pseudoprogression. The patient restarted nivolumab and continues to have a near complete response. Conventional chondrosarcoma may be sensitive to checkpoint inhibitors. Further, this case demonstrates clearly the phenomenon of pseudo-progression in this disease, a factor that must be considered in the design of clinical trials and clinical care. This case supports additional study of immunomodulatory agents in this deadly disease.

Twitter Demographics

The data shown below were collected from the profiles of 9 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 7 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 7 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 2 29%
Researcher 1 14%
Lecturer 1 14%
Other 1 14%
Unknown 2 29%
Readers by discipline Count As %
Medicine and Dentistry 2 29%
Neuroscience 2 29%
Biochemistry, Genetics and Molecular Biology 1 14%
Unknown 2 29%

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 November 2018.
All research outputs
#4,125,417
of 16,669,654 outputs
Outputs from Journal for Immunotherapy of Cancer
#646
of 1,597 outputs
Outputs of similar age
#84,386
of 281,108 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#2
of 2 outputs
Altmetric has tracked 16,669,654 research outputs across all sources so far. Compared to these this one has done well and is in the 75th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,597 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 13.7. This one has gotten more attention than average, scoring higher than 59% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 281,108 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.
We're also able to compare this research output to 2 others from the same source and published within six weeks on either side of this one.